Drug intelligence / Profile preview

berberine + bezafibrate

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of berberine and bezafibrate used for the treatment of mixed dyslipidemia. This combination has been shown to significantly reduce triglycerides, total cholesterol, LDL cholesterol, and VLDL levels in patients with mixed dyslipidemia. In clinical trials, the combination therapy remitted the diagnosis of mixed dyslipidemia in 90% of patients.

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on berberine + bezafibrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on berberine + bezafibrate.

Explore the full profile